Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.